Arterra Bioscience (ARBS) H2 2024 earnings summary

Executive summary

• Production value reached €5.3 million, up 6.37% year-over-year, driven by a 33.7% increase in cosmetic raw material sales.

• Net profit rose to €1.34 million, a 24.21% increase year-over-year, with a net margin of 25.38%.

• EBITDA grew 7.60% to €1.7 million (margin 32.52%), and EBIT increased 29.77% to €1.7 million (margin 32.34%).

• Net financial position remained positive at €5.4 million in cash, slightly down due to investments and increased receivables.

• Five new cosmetic products launched, with five more in development for 2025; significant R&D progress in vegan collagen and powder actives.

Financial highlights

• Sales revenue increased 26.3% year-over-year to €4.17 million.

• Personnel costs rose 8.29% due to employee level upgrades and salary increases.

• Amortization expenses fell 36.26% as AIM listing costs were fully amortized.

• Financial income improved 30.32%, mainly from higher dividends from Vitalab S.r.l.

• Equity increased to €11.4 million from €10.8 million year-over-year.

Outlook and guidance

• Positive growth trend confirmed by late 2024 and early 2025 results, with optimism for achieving 2025 targets.

• Continued R&D progress and new product launches expected to support further growth.